Zhang et al. demonstrated that TAMs directly contribute to 5-FU chemoresistance in CRC and concluded that TAM pathways (such as CCL2) were potential immunotherapy targets to increase the efficacy of 5-FU chemotherapy [13]. Here, CCL2 is linked to colorectal carcinoma.